Albemarle Q2 net sales, adjusted EPS beats estimates
Overview
Albemarle Q2 net sales of $1.3 bln beat analyst expectations, per LSEG data
Adjusted EPS for Q2 beats consensus, per LSEG data
Co reduces full-year 2025 capital expenditure outlook to $650-$700 mln
Outlook
Albemarle expects full-year 2025 net sales of $4.9 - $5.2 bln
Company projects 2025 adjusted EBITDA between $0.8 - $1.0 bln
Albemarle reduces 2025 capital expenditure outlook to $650 - $700 mln
Company anticipates positive free cash flow for 2025
Result Drivers
ENERGY STORAGE VOLUMES - Record production from integrated conversion network led to 15% volume growth in Energy Storage
SPECIALTIES DEMAND - Higher demand and productivity initiatives increased Specialties adjusted EBITDA by 34.7%
COST SAVINGS - Improved fixed cost absorption and ongoing cost savings supported adjusted EBITDA despite lower lithium pricing
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Net sales | Beat | $1.33 bln | $1.22 bln (18 Analysts) |
Q2 Adjusted EPS | Beat | $0.11 | -$0.82 (20 Analysts) |
Q2 EPS |
| -$0.16 |
|
Q2 Adjusted EBITDA | Beat | $336.50 mln | $195.70 mln (18 Analysts) |
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 9 "strong buy" or "buy", 15 "hold" and 4 "sell" or "strong sell"
The average consensus recommendation for the specialty chemicals peer group is "buy."
Wall Street's median 12-month price target for Albemarle Corp is $75.50, about 5.2% above its July 29 closing price of $71.60
Press Release: ID:nPn2Rfv3ya
